title: Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics.
abstract: Although biapenem is used in the treatment of pneumonia, the clinical data on elderly patients are yet insufficient. Therefore, the purpose of this study was evaluating the efficacy and safety of biapenem against pneumonia in the elderly and its pharmacokinetics. The subjects were patients 65 years of age or older with pneumonia. Biapenem (300 mg) was administered once to three times per day. For some cases, the drug concentrations in plasma were measured chronologically. The clinical efficacy was evaluated in reference to the improvement in subjective symptoms and objective opinion. The primary outcome was efficacy rate at the end of treatment. Biapenem was effective in 17 of 20 subject cases (85.0 %). Regarding safety, although 4 cases experienced hepatic dysfunction and 1 case had nausea, these effects were not severe in all cases and administration was continued. There was no deterioration of renal function associated with biapenem. In 13 cases in which the trough value of biapenem was measured, there were no unacceptable side effects and the trough values were generally low. It is believed that biapenem (300 mg once to three times a day), even when taken by elderly people, does not accumulate and that the dosage is safe and appropriate. The changes in the predicted concentrations calculated with the pharmacokinetic-pharmacodynamic (PK-PD) software, which is based on previously reported population pharmacokinetic parameters, and those in the measured concentrations approximately matched. It is useful to plan biapenem administration using the PK-PD software when performing antibiotic chemical treatment.
authors.affiliation: Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan. fumi1224@med.shimane-u.ac.jp
authors.forename: Fumi
authors.initials: F
authors.lastname: Karino
authors.forename: Naoko
authors.initials: N
authors.lastname: Deguchi
authors.forename: Hibiki
authors.initials: H
authors.lastname: Kanda
authors.forename: Miki
authors.initials: M
authors.lastname: Ohe
authors.forename: Keiichi
authors.initials: K
authors.lastname: Kondo
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Tada
authors.forename: Takashige
authors.initials: T
authors.lastname: Kuraki
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nishimura
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Moriyama
authors.forename: Kazuro
authors.initials: K
authors.lastname: Ikawa
authors.forename: Norifumi
authors.initials: N
authors.lastname: Morikawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Isobe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013845:Thienamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; C065257:biapenem